Heart Test Laboratories Receives FDA Breakthrough Designation

Heart Test Laboratories, Inc. ( (HSCS) ) just unveiled an announcement.

On June 4, 2025, HeartSciences Inc. announced that it received the FDA’s Breakthrough Device designation for its AI-driven ECG algorithm designed to detect aortic stenosis. This algorithm, integrated with hospital EHR systems, promises early detection of this serious heart condition, potentially transforming patient outcomes by enabling timely interventions.

The most recent analyst rating on (HSCS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.

Spark’s Take on HSCS Stock

According to Spark, TipRanks’ AI Analyst, HSCS is a Neutral.

The overall score is primarily influenced by the company’s significant financial challenges, which are a major risk factor. However, the stock’s technical momentum and the recent strategic patent grant provide some positive offsetting factors. The lack of earnings call data limits further insights into company guidance and sentiment.

To see Spark’s full report on HSCS stock, click here.

More about Heart Test Laboratories, Inc.

HeartSciences is a medical technology company specializing in AI-based advancements for ECGs, aiming to enhance cardiac screening tools in clinical settings. The company offers AI-ECG algorithms through a cloud-based platform and low-cost ECG hardware, focusing on seamless integration into existing clinical care pathways.

Average Trading Volume: 16,821

Technical Sentiment Signal: Sell

Current Market Cap: $3.99M

For detailed information about HSCS stock, go to TipRanks’ Stock Analysis page.